Back to top

Analyst Blog

Zacks Equity Research

AMAG Beats Riding on Feraheme Sales

AMAG

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) posted first quarter 2012 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and the year-ago loss of $1.05 per share. Higher revenues and lower operating expenses boosted earnings.

Quarterly revenues climbed 15.7% year-over-year to $15.5 million, just above the Zacks Consensus Estimate of $15 million. Increased sales of the company’s sole-marketed product, Feraheme, contributed to the revenue growth.

Quarterly Highlights

AMAG records revenue mainly from Feraheme, an injectable drug for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adults suffering from chronic kidney disease (CKD).

In the reported quarter, net sales of Feraheme amounted to $13.6 million, up from $10.9 million reported in the first quarter of 2011. Additionally, Feraheme non-dialysis provider demand in first quarter of 2012 was 30% higher than the prior-year quarter and 10% higher than the fourth quarter of 2011.

Total operating costs (including cost of goods sold) in the quarter amounted to $28.3 million, down from $36.2 million recorded in the first quarter of 2011, as a result of the company’s restructuring plans announced in the fourth quarter of 2011. Both research & development (R&D) expenses and selling, general and administrative (SG&A) expenses were on the downswing in the reported quarter.

Outlook Reaffirmed

The company reiterated its guidance for 2012. It expects total revenue of about $79 – $83 million. The Zacks Consensus Estimate of $77 million lies within the company’s guidance range.

For 2012, Feraheme sales are expected to amount to $53 - $57 million, excluding any royalties from sales in the ex-US markets.

Further, AMAG expects operating expenses (excluding cost of goods sold) in the range of $90 - $95 million, with R&D expenses expected in the range of $40 - $45 million and SG&A expenses amounting to $50 - $55 million.

The company expects to end 2012 with cash and investments of $225 - $300 million.

Our Take

We currently have a Neutral recommendation on the stock. The stock carries a Zacks #3 Rank (short-term Hold rating). We expect AMAG to become cash flow positive by the end of 2012 riding on Feraheme’s uptake.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%